A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Durvalumab; Drug: Selumetinib; Drug: Capivasertib; Drug: Danvatirsen; Drug: Oleclumab; Drug: Paclitaxel Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials